Metabolic reprogramming is emerging as a prominent characteristic of most disorders affecting the human kidney and leading to Chronic Kidney Disease (CKD). The kidney has long been recognized as a central metabolic hub of the human organism able to finely regulate the plasma concentration of ions as well as that of metabolites. In the past decade the centrality of metabolic rewiring and the mitochondrial contribution to a number of disorders such as acute kidney injury, chronic kidney disease, diabetic nephropathy and genetic disorders of the kidney such as Autosomal Dominant Polycystic Kidney Disease (ADPKD) has emerged.
The goal of the current Research Topic is to provide a comprehensive overview of topics that cover the centrality of metabolic rewiring and mitochondrial function in different settings of renal disorders including those originating from primary alterations of mitochondria and extending to those in which metabolic reprogramming and mitochondria dysfunction has been more recently discovered. Both glomerulopathies and tubulopathies will be covered, as well as description of key metabolic needs in the individual districts in physiological conditions and during development will be covered.
The scope is to provide an up to date view of the metabolic requirements of glomerular and tubular structures of the nephron during development, as well as in adult physiology and in disease.
The laboratory of Dr. Katalin Susztak received financial support from GSK, Merck, Gilead, Novo Nordisk, Regeneron, Bayer and Boehringer Ingelheim. Dr. Alessandra Boletta declares no competing interests with regard to the Research Topic subject
Metabolic reprogramming is emerging as a prominent characteristic of most disorders affecting the human kidney and leading to Chronic Kidney Disease (CKD). The kidney has long been recognized as a central metabolic hub of the human organism able to finely regulate the plasma concentration of ions as well as that of metabolites. In the past decade the centrality of metabolic rewiring and the mitochondrial contribution to a number of disorders such as acute kidney injury, chronic kidney disease, diabetic nephropathy and genetic disorders of the kidney such as Autosomal Dominant Polycystic Kidney Disease (ADPKD) has emerged.
The goal of the current Research Topic is to provide a comprehensive overview of topics that cover the centrality of metabolic rewiring and mitochondrial function in different settings of renal disorders including those originating from primary alterations of mitochondria and extending to those in which metabolic reprogramming and mitochondria dysfunction has been more recently discovered. Both glomerulopathies and tubulopathies will be covered, as well as description of key metabolic needs in the individual districts in physiological conditions and during development will be covered.
The scope is to provide an up to date view of the metabolic requirements of glomerular and tubular structures of the nephron during development, as well as in adult physiology and in disease.
The laboratory of Dr. Katalin Susztak received financial support from GSK, Merck, Gilead, Novo Nordisk, Regeneron, Bayer and Boehringer Ingelheim. Dr. Alessandra Boletta declares no competing interests with regard to the Research Topic subject
